Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-08-04 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2023-08-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter dated August 4, 2023, addressed to stock exchanges (BSE and NSE) informing them about the availability of the audio recording of the company's earnings call for the quarter ended June 30, 2023 (Q1 FY 2023-24). It references the earnings call and provides a link to the recording on the company's website. The document itself does not contain the transcript or detailed financial data but is an announcement about the availability of the earnings call recording. Given the content and length (2172 characters), it is not the earnings release or call transcript itself but an announcement related to the earnings call. Therefore, the most appropriate classification is Call Transcript (CT) because it relates directly to the earnings call audio recording, which is a form of call transcript material, even though the transcript text is not included here. The document is not a report publication announcement (RPA) because it specifically refers to the earnings call audio recording, which falls under call transcripts category.
2023-08-04 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings
2023-08-04 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the Quarter ended June 30, 2023' and is issued by ICICI Bank Limited as the monitoring agency for Supriya Lifescience Limited. It is pursuant to SEBI regulations related to the utilization of IPO proceeds. The report details the utilization of funds raised through the IPO, including tables showing original and revised costs, amounts utilized, unutilized amounts, and investments of unutilized proceeds. It also includes declarations about no deviation from the objects of the issue and no conflict of interest. The document contains substantive financial data and analysis related to the quarter ended June 30, 2023. It is not an announcement of a report but the actual monitoring report itself. This type of report is a regulatory requirement to monitor the use of IPO proceeds and is classified as a Capital/Financing Update (CAP) because it relates to the monitoring of capital raised and its utilization, not a full annual or quarterly financial report or audit report. Therefore, the appropriate classification is CAP with high confidence.
2023-08-04 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated August 4, 2023, announcing the financial results of Supriya Lifescience Ltd for the quarter ended June 30, 2023 (Q1FY24). It includes key financial highlights such as revenue, PAT, EBITDA, and margins, along with commentary from the Chairman and Managing Director. The document is explicitly labeled as a "Press Release" and is addressed to stock exchanges pursuant to SEBI regulations. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR), but rather a summary of key financial metrics and business updates. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. The document length (5499 characters) and content confirm it is the earnings announcement itself, not just a notice or link to a report. Therefore, the correct classification is Earnings Release (ER).
2023-08-04 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Earnings Presentation Q1FY24' and contains detailed financial data for the first quarter of fiscal year 2024, including revenue, EBITDA, PBT, PAT, margins, and segment performance. It includes a Chairman's message, business overview, historical financial performance, and future outlook. The document is 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The content is consistent with an investor presentation focusing on quarterly financial results and company strategy. Therefore, the document fits the category of an Investor Presentation (IP).
2023-08-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.